IDNA - ETF AI Analysis

Top Page

iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA)

Rating:57Neutral

Price Target:―

The ETF IDNA's overall rating reflects a mix of strong and weaker holdings. High-performing stocks like Regeneron and Incyte contribute positively due to their solid financial health, impressive revenue growth, and strategic R&D investments, which position them well for future growth. However, weaker holdings such as Celcuity and Arcellx, with poor financial performance and valuation challenges, weigh down the fund's rating. A key risk factor is the ETF's concentration in the biotech sector, which is inherently volatile and subject to high financial and clinical uncertainties.

Positive Factors

Strong Year-to-Date Performance

The ETF has delivered solid returns so far this year, indicating strong momentum in its holdings.

Global Diversification

While primarily focused on the U.S., the fund also includes exposure to other regions like Europe and Asia, adding geographic diversity.

Reasonable Expense Ratio

The ETF's expense ratio is relatively low compared to many specialized funds, helping investors keep more of their returns.

Negative Factors

Sector Concentration

The fund is heavily concentrated in the healthcare sector, which could make it vulnerable to industry-specific risks.

Underperforming Holdings

Some top holdings, such as Regeneron and Merck, have shown weak performance this year, which could drag on overall returns.

Small Asset Base

The ETF has relatively low assets under management, which could lead to higher trading costs and less liquidity for investors.

IDNA vs. SPDR S&P 500 ETF (SPY)

AUM131.08M

RegionGlobal

Expense Ratio0.47%

Beta0.91

IssueriShares

Inception DateJun 11, 2019

Dividend Yield0.99%

Asset ClassEquity

Index TrackedNYSE FactSet Global Genomics and Immuno Biopharma Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume29,567

30 Day Avg. Volume32,027

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

38.34

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering41

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

IDNA Summary

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an investment fund that focuses on companies leading advancements in genomics, immunology, and healthcare. It includes businesses working on cutting-edge technologies like gene editing, genome sequencing, and personalized medicine. Some of its top holdings are well-known healthcare companies like Regeneron and AstraZeneca. Investors might consider IDNA for its potential long-term growth in the rapidly evolving healthcare and biotechnology sectors. However, it’s important to know that this ETF is heavily focused on healthcare, meaning its performance can be affected by changes in that industry or regulatory challenges.

How much will it cost me?The iShares Genomics Immunology and Healthcare ETF (IDNA) has an expense ratio of 0.47%, which means you’ll pay $4.70 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused fund that requires active management to track innovative companies in genomics and healthcare. The higher cost reflects the specialized nature of the fund.

What would affect this ETF?The IDNA ETF, focused on genomics and healthcare innovation, could benefit from advancements in gene editing, personalized medicine, and increased global healthcare spending, which may drive growth in its top holdings like Revolution Medicines and Regeneron. However, it faces risks from regulatory hurdles, high research costs, and potential market volatility in the healthcare sector, which could impact the performance of companies within the fund. Global economic conditions and changes in government healthcare policies could also influence the ETF's future performance.

IDNA Top 10 Holdings

The IDNA ETF is heavily concentrated in healthcare, with a focus on genomics and immunology, showcasing a mix of rising stars and steady performers. Revolution Medicines and Celcuity are driving excitement with promising pipelines, though their financial challenges keep them in the speculative zone. Regeneron and AstraZeneca provide stability, leveraging strong revenue growth and strategic R&D investments, while BeiGene adds a global flavor with its leadership in immunotherapy despite profitability hurdles. Overall, the fund’s positioning leans heavily into innovation, but its reliance on early-stage biotech names introduces some volatility.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
RVMD	Revolution Medicines	6.09%	$7.89M	$14.65B	46.33%	52 Neutral
CELC	Celcuity	5.66%	$7.34M	$4.56B	679.77%	44 Neutral
REGN	Regeneron	5.02%	$6.51M	$78.84B	0.07%	78 Outperform
INCY	Incyte	4.90%	$6.35M	$20.03B	41.66%	81 Outperform
	―	4.68%	$6.06M	―	―	―
6160	BeiGene Ltd	4.31%	$5.59M	HK$303.79B	65.12%	55 Neutral
MRK	Merck & Company	4.26%	$5.52M	$252.74B	1.21%	76 Outperform
AZN	AstraZeneca	4.10%	$5.31M	£214.50B	31.10%	78 Outperform
ROG	Roche Holding AG	3.86%	$5.00M	CHF247.26B	36.34%	73 Outperform
GSK	GlaxoSmithKline	3.80%	$4.93M	£72.68B	34.18%	82 Outperform

IDNA Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

25.01

Positive

100DMA

23.57

Positive

200DMA

22.13

Positive

Market Momentum

MACD

0.64

Negative

RSI

59.73

Neutral

STOCH

80.71

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDNA, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 26.01, equal to the 50-day MA of 25.01, and equal to the 200-day MA of 22.13, indicating a bullish trend. The MACD of 0.64 indicates Negative momentum. The RSI at 59.73 is Neutral, neither overbought nor oversold. The STOCH value of 80.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDNA.

IDNA Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
IDNA	―	―	$131.08M	0.47%	―
CHAT	―	―	$995.84M	0.75%	―
CRBN	―	―	$989.25M	0.20%	―
BUG	―	―	$988.25M	0.51%	―
IVES	―	―	$959.26M	0.75%	―
TAN	―	―	$949.79M	0.71%	―

Performance Comparison

IDNA

iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund

26.76

2.97

12.48%

CHAT

Roundhill Generative AI & Technology ETF

―

CRBN

iShares MSCI ACWI Low Carbon Target ETF

―

BUG

Global X Cybersecurity Etf

―

IVES

Dan IVES Wedbush AI Revolution ETF

―

TAN

Invesco Solar ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents